Feed aggregator

Sage's MDD Treatment Fails to Distinguish Itself from Placebo in Late-Stage Trial

Biospace news - Thu, 12/05/2019 - 02:00
The Phase III failure was certainly a setback for the company as it chased Janssen and its Esketamine-based treatment Spravato for MDD.

Reviewers of Chinese CRISPR Research: "Ludicrous" and "Dubious At Best"

Biospace news - Thu, 12/05/2019 - 02:00
The analysis found 13 key problems, but one of the most relevant is that the stated purpose of the research—which is also under attack—did not occur.

BioSpace Global Roundup, Dec. 5

Biospace news - Thu, 12/05/2019 - 02:00
Companies from across the globe provide updates on their business and pipelines.

CARB-X Supports Vedanta Biosciences Multi-Drug Resistant Asset with $5.8 Million Grant

Biospace news - Thu, 12/05/2019 - 02:00
Vedanta’s VE707 microbiome program, which is still in the preclinical stage, is designed to restore healthy microbiota and prevent infection and colonization recurrence by multi-drug-resistant superbugs.

Demystifying Interview Questions: “Tell Me About Yourself”

Biospace news - Thu, 12/05/2019 - 02:00
While many job seekers are unnerved by the “Tell me about yourself” request, it’s actually an opportunity to shine and take control of the interview.

Acadia's Nuplazid Hits the Mark in Late-Stage Dementia-Related Psychosis Trial

Biospace news - Thu, 12/05/2019 - 02:00
The company presented full trial data at the 12th Clinical Trials on Alzheimer’s Disease meeting in San Diego on Wednesday.

Practicing for an Interview: Rehearsed, Mock and Video-Recorded Interviews

Biospace news - Thu, 12/05/2019 - 02:00
Practice will help you reduce interview anxiety, improve your interview skills, and in many cases, gain important feedback about how you interview.

Aurinia's Voclosporin for Kidney Disease Caused by Lupus Hits Mark in Phase III

Biospace news - Thu, 12/05/2019 - 02:00
“This extraordinary pivotal data confirms voclosporin’s ability to achieve statistically significant improvements in clinically meaningful endpoints for this complex disease, with a comparable safety profile to the current standard of care,” said Neil Solomons, Aurinia’s chief medical officer.

A conversation with Bob Volkmann, Founder of BioPharma Works– remotely managing multi-functional ...

Biospace news - Thu, 12/05/2019 - 02:00
Saurabh Kapure, Vice President, Business Development, USA for Jubilant Biosys, recently sat down with Bob Volkmann, PhD, Founder and Chief Scientific Officer, at BioPharmaWorks.

AWS announces strategic collaboration with Novartis to accelerate digital transformation of its business operations

World Pharma News - Wed, 12/04/2019 - 16:00
Today, Amazon Web Services, Inc. (AWS), an Amazon.com company (NASDAQ: AMZN), announced a multi-year strategic collaboration with Novartis to reimagine this leading pharmaceutical company's core pharmaceutical manufacturing, supply chain, and delivery operations using AWS's portfolio of cloud services.

The gut may be involved in the development of multiple sclerosis

World Pharma News - Wed, 12/04/2019 - 11:00
It is incompletely understood which factors in patients with multiple sclerosis (MS) act as a trigger for the immune system to attack the brain and spinal cord. A potential factor is described by a research team in the journal Proceedings of the National Academy of Sciences, PNAS. The medical researchers used an animal model to show that the protein Smad7 mobilises immune cells in the intestines which, in turn, trigger inflammation in the central nervous system.

Genentech Earns Another Lung Cancer Approval for Tecentriq

Biospace news - Wed, 12/04/2019 - 02:00
The U.S. Food and Drug Administration approved Genentech’s Tecentriq plus chemotherapy as a first-line treatment of metastatic non-squamous non-small cell lung cancer.

White House Claims Pelosi Plan Would Cause Loss of 100 New Drugs Over 10 Years

Biospace news - Wed, 12/04/2019 - 02:00
Two weeks after the pharmaceutical industry predicted dire consequences for innovation if the prescription price reduction plan proposed by House Speaker Nancy Pelosi passes, the White House is now echoing those concerns but suggesting even worse outcomes than industry analysts predict.

Preview: The 12th Clinical Trials on Alzheimer’s Disease Conference

Biospace news - Wed, 12/04/2019 - 02:00
Researchers from around the world are coming to present scientific research and clinical trial data for the disease.

Demystifying Interview Questions: ‘What Are Your Strengths?’

Biospace news - Wed, 12/04/2019 - 02:00
What will it take to motivate the employer to hire you, or at least invite you back for a second interview?

Cyrus and Broad Partner on CRISPR Enzyme Engineering

Biospace news - Wed, 12/04/2019 - 02:00
Although there have been numerous variations on CRISPR that improve its effectiveness and apparent safety, there are still concerns about off-target edits and immune reactions to the Cas9 enzyme used to cut DNA.

Will Biogen's Stock Soar or Implode on Alzheimer's Data?

Biospace news - Wed, 12/04/2019 - 02:00
The 12th Clinical Trials on Alzheimer’s Disease conference kicks off today. One of the big stories, which will be presented on Thursday, December 5, is detailed results from Biogen’s Phase III clinical trials of aducanumab.

Top 7 Companies in Biotech Beach by Revenue

Biospace news - Wed, 12/04/2019 - 02:00
The seven featured companies are the top companies headquartered in Biotech Beach based on 2018 revenue.

Current Trends in Synthetic Biology

Biospace news - Wed, 12/04/2019 - 02:00
Several trends have emerged in synthetic biology since the field developed nearly 20 years ago. In that time, some technologies have crystallized and developed into key trends that crop up time again within synthetic biology conversations.

Richard Sackler Sought to ‘Play Down’ Risk Concerns of OxyContin: Report

Biospace news - Wed, 12/04/2019 - 02:00
Richard Sackler, the former president of Purdue Pharma, wanted prescribers to know that when it comes to treating pain, OxyContin was the way to go. And, in order to boost those sales, that meant the company had to downplay any concerns regarding the risk of addiction.